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Purpose: The aim of this study was to evaluate the
pharmacokinetic (PK) proﬁle and tolerability of lur-
asidone in children and adolescents with a range of
psychiatric disorders.
Methods: This multicenter, open-label, single and
multiple ascending-dose study of the PK proﬁle of
lurasidone (20, 40, 80, 120, and 160 mg/d) enrolled
outpatients aged 6 to 17 years with a diagnosis of
attention deﬁcit/hyperactivity disorder, bipolar spectrum
disorder, or other psychiatric disorder. Serial blood
samples were collected for analysis of PK parameters,
including Cmax, Tmax, and AUC0–24.
Findings: Exposure (Cmax and AUC0–24) to lurasi-
done and its active metabolites showed linear in-
creases across the entire dose range. Slope estimates
(95% CI) across the dose range studied was 0.90 ng 
h/mL (0.74–1.06) for AUC0–24 and 0.70 ng/mL (0.52–
0.87) for Cmax on day 10 or 12. Lurasidone exposure,
after multiple-dose administration in this child and
adolescent population, was similar to exposure ob-
served at steady state in adults. The effects of dose on
exposure to the 3 active metabolites of lurasidone
were linear and similar after the administration of
single and multiple doses. Adverse events were qual-
itatively similar to those reported in adults. Discontin-
uations due to adverse events were dose related, with
doses o120 mg/d being better tolerated than higher
doses, especially in younger children.
Implications: In this child and adolescent population,
exposure parameters for lurasidone and its active metab-
olites were dose proportional in the range of 20 to 160
mg/d after the administration of single and multiple
doses. These results suggest that lurasidone doses o120
mg/d were better tolerated compared with higher doses,
especially in younger children. ClinicalTrials.gov identi-
ﬁer: NCT01620060. (Clin Ther. 2015;37:2788–2797)2788& 2015 The Authors. Published by Elsevier HS
Journals, Inc.
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INTRODUCTION
Lurasidone is an atypical antipsychotic agent with a
distinctive pharmacologic proﬁle characterized by high-
afﬁnity binding at serotonin (5-HT)-7 receptors (ki ¼
0.5 nM; antagonist) that is comparable to its afﬁnity
for dopamine-2 and 5-HT2A receptors. In addition,
lurasidone has moderate afﬁnity for 5-HT1A receptors,
and minimal to no afﬁnity for H1 and M1 receptors.
1
The use of lurasidone was approved by the US Food
and Drug Administration in October 2010 for the
treatment of adults with schizophrenia, and in July
2013 for the treatment of adults with bipolar
depression, both as monotherapy and as adjunctive
therapy with lithium or valproate. The efﬁcacy of
lurasidone at doses ranging from 20 to 160 mg/d has
been investigated in adults with schizophrenia/
schizoaffective disorder2–5 and bipolar disorder.6,7
Lurasidone is rapidly absorbed after oral admin-
istration, with a mean Tmax in serum of 1.3 hours.
8 In
a study in healthy adult volunteers, 9% to 19% of a
given dose was absorbed; absorption was reported to
have been linear at doses ranging up to 100 mg/d in
healthy volunteers and up to 160 mg/d in individuals
with schizophrenia.8 The mean t½ of single-dose
lurasidone up to 100 mg/d ranged from 12.2 to 18.3Volume 37 Number 12
R.L. Findling et al.hours and increased to 36 hours at steady state (day 9) in
healthy volunteers.8 In adult subjects with schizophrenia
administered single doses of 120 to 160 mg/d, the
mean t½ was 28.8 to 37.4 hours.
8 In a study of
multiple-dose lurasidone 120 mg/d in patients with
schizophrenia or schizoaffective disorder, steady state
was achieved by day 5.9
Lurasidone is primarily metabolized by cytochrome
P-450 (CYP) 3A4 and is not a substrate of CYP1A1,
1A2, 2A6, 4A11, 2B6, 2C8, 2C9, 2C19, 2D6, or 2E1
isozymes. The major biotransformation pathways are
oxidative N-dealkylation, hydroxylation of norbornane
ring, and S-oxidation. These pathways produce 2 phar-
macologically active metabolites, ID-14283 (the exohy-
droxy metabolite) and ID-14326, which represent 25%
and 3% of the parent exposure, respectively, and a third
minor active metabolite (ID-11614), accounting for 1%.8
Lurasidone does not induce or inhibit any CYP enzymes.
The half-life of the primary active metabolite (ID-14283)
is shorter than that of lurasidone, but ID-14283 otherwise
has similar pharmacologic and in vivo characteristics.8
Data on the PK proﬁle of atypical antipsychotics in
child and adolescent patients is important, especially in
light of the notable increase in the rate antipsychotic medi-
cation use in this population over the past 20 years.10,11
The primary objective of the present study was to
characterize the PK and tolerability proﬁle of single
and multiple oral doses of lurasidone (20, 40, 80, 120,
or 160 mg/d) in a child and adolescent population
(aged 6–17 years). The secondary objective was to
characterize the PK proﬁle of lurasidone metabolites
in this population.PATIENTS AND METHODS
The study protocol was approved by a central institu-
tional review board (Sterling IRB, Atlanta, Georgia),
and the study was conducted in accordance with the
principles of Good Clinical Practice and the Declara-
tion of Helsinki. Patients were enrolled at 8 clinical
sites in the United States between June 2012 and May
2013. Before any study procedures were performed,
informed consent from the parent or guardian of each
child, as well as each patient’s assent (or informed
consent from emancipated patients), were obtained.Study Participants
Screening procedures/assessments to determine study
eligibility included demographic characteristics and aDecember 2015complete medical history (including complete medication
history), vital sign measurements (supine and standing
blood pressure, heart rate, and body temperature),
height and weight, complete physical examination (in-
cluding a mental status examination), standard 12-lead
ECG (the ECG was read by a central core laboratory,
and the read results were used for determining eligibil-
ity), clinical laboratory tests (urine drug test and breath
alcohol test; hepatitis B and C [only in patients without a
documented history]; chemistry [including prolactin],
hematology, and urinalysis; and serum pregnancy test
[conducted only in female patients aged Z8 years]).
Eligible subjects were male or female outpatients
between the ages of 6 and 17 years (inclusive) with a
diagnosis of schizophrenia spectrum disorder, bipolar
spectrum disorder, autism spectrum disorder, atten-
tion deﬁcit/hyperactivity disorder with aggressive be-
havior (ie, comorbid conduct disorder or other
disruptive behavior disorder), or Tourette’s syndrome.
Patients were excluded if they had clinically signiﬁcant
alcohol or drug abuse/dependence within the previous
6 months or a positive breath alcohol test or urine
screen for drugs of abuse at screening; severe cognitive
impairment; clinical instability or an imminent risk for
suicide or injury to self, others, or property; a
clinically signiﬁcant major medical condition or ab-
normal laboratory value or vital sign measurement;
and/or pregnancy, breastfeeding, or sexual activity
without the use of medically approved birth control.
Psychotropic medications were tapered and discon-
tinued at least 3 days before the administration of the
ﬁrst dose of lurasidone, with the exception of ﬂuox-
etine (discontinued for Z28 days) and monoamine
oxidase inhibitors (discontinued for Z14 days). In-
hibitors or inducers of CYP3A4 or any medication
that could have signiﬁcantly prolonged the QT/QTc
interval was not to be taken within 28 days before
study drug administration or at any point during the
study and until study termination.
Study Design
In this multicenter, open-label, single and multiple
ascending-dose study, patients were stratiﬁed into 1 of
4 age groups (6–9, 10–12, 13–15, and 16–17 years)
(Figure 1). Dose cohorts were entered into the study
sequentially, beginning with the 20-mg/d dose group.
Sequentially escalated doses (40, 80, 120, or 160 mg/d)
were administered to newly entered patients after PK
and tolerability data from the previous dosing cohort2789
Clinical Therapeuticshad been reviewed. Dose escalation was stopped if a
dose level was not well tolerated by a given age group.
Enrollment of patients continued until a target of 12
completed patients per age group, per dose, was
achieved.
All patients received a single dose of lurasidone
followed by a 2-day washout period, and then
once-daily dosing of lurasidone for 7 days (20- to
120-mg/d cohorts) or 9 days (160 mg/d cohort).
Patients were started at the assigned dose, except for
the 120 mg/d and 160 mg/d dosages, which were
titrated to the assigned dose. The following dosing
schemes were used: 120-mg/d cohort: day 1, 80 mg/d;
days 4 and 5, 80 mg/d; and days 6 to 10, 120 mg/d;
160-mg/d cohort: day 1, 80 mg/d; days 4 and 5,
80 mg; days 6 and 7, 120 mg/d; and days 8 to
12, 160 mg/d.
In patients in the 20- to 120-mg/d cohorts, there
was a screening period (from days –28 to –2),
followed by a study period (from days –1 to 11),
and a follow-up visit (on day 18  3). During the
study period, patients underwent 2 inpatient visits
(between days –1 and 2, and between days 9 and 11)
for dosing and study assessments, 3 outpatient visitsScreening Day -28 to -2
Age Groups
Lurasidone Sing
20, 40, or 8
20 mg
40 mg
80 mg
6-9 years
10-12 years
13-15 years
16-17 years
Lurasidone
Dose Cohorts
120 mg
160 mg
-1 1
Lurasidon
Single Dose: 
-1 1
Lurasidone 
Single Dose: 80 
-1 1 2
Figure 1. Study design.
2790(on days 3, 5, and 7), and a telephone contact (on day
6) for the assessment of tolerability and study drug
adherence.
In the 160-mg/d cohort only, there was a screening
period (from days –28 to –2), followed by a study
period (from days –1 to 13), and a follow-up visit
(on day 20  3). During the study period, patients
underwent 2 inpatient visits (between days –1 and 2,
and between days 11 and 13) for dosing and study
assessments, 3 outpatient visits (on days 3, 5, and 7),
and a telephone contact (on day 6) for the assessment
of tolerability and study drug adherence. In this
cohort, patients were allowed to remain as inpatients
from days –1 through 13. At the discretion of the
investigator, patients were allowed to remain as
inpatients from days –1 through 11.
Lurasidone was administered in the morning within
30 minutes after a breakfast of at least 350 kcal.
A standardized breakfast was provided on days 1, 2,
10, and 11 (20- to 120-mg/d cohorts) or on days 1, 2,
12, and 13 (160-mg/d cohort). Ingestion of alcohol,
caffeine, grapefruit or orange juice, and a total daily
caloric intake in excess of 3000 kcal were prohibited
during the course of the study.Inpatient
le Dose
0 mg
Lurasidone Multiple Dose: 7 days
20, 40, or 80 mg
OutpatientStudy Day
2 3 4 5 6 7 8 9 1110
e 
80 mg
Lurasidone 80 mg Days 4-5,
120 mg Days 6-10
2 3 4 5 6 7 8 9 1110
mg
Lurasidone 80 mg Days 4-5,
120 mg Days 6-7, 160 mg Days 8-12
3 4 5 6 7 8 9 1110 12 13
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Blood samples for PK analysis were collected
predose on day 1 and over 48 hours postdose
(at 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours) in the
single-dose period, and predose on day 10 or 12 and
at 0.5, 1, 2, 4, 6, 8, 12, and 24 hours postdose in the
multiple-dose period of the study. Blood samples were
collected from a forearm vein, primarily using an
indwelling venous catheter (some samples were ob-
tained by a single blood draw) into a 6.0-mL lavender-
top Vacutainer (Becton, Dickinson and Company,
Franklin Lakes, New Jersey) (or equivalent) collection
tube containing EDTA as an anticoagulant. Samples
were stored at –101C to –301C until analysis.
Determination of Plasma Concentrations of
Lurasidone and Metabolites
All analyses were carried out at Covance Laborato-
ries Inc (Madison, Wisconsin). Lurasidone and its active
metabolites (ID-14283, ID-14326, and ID-11614) were
extracted from the blood samples using a validated
liquid–liquid extraction. After evaporation under nitro-
gen, the residue was reconstituted and analyzed using
LC-MS/MS. The 2 inactive metabolites (ID-20219 and
ID-20220) were extracted using protein precipitation.
The supernatant was then diluted and analyzed using
LC-MS/MS. For the measurement of the concentration
of lurasidone and its active metabolites, overall assay
precision (relative SD of quality-control samples) was in
the range of 4.9% to 9.4%, and accuracy in terms of
relative error percentage was in the range of –5.5% to
1.5%. For the measurement of the concentrations of the
2 inactive metabolites, overall assay precision values
(relative SD percentage of quality-control samples) were
4.3% to 8.6%, and accuracy values (relative error
percentage) were –1.1% to 2.4%.
Pharmacokinetic Analysis
PK parameters were derived using noncompartmen-
tal methods with WinNonlin Professional version 5.2
(Pharsight Corp, Mountain View, California). All PK
computations were performed using WinNonlin Pro-
fessional version 5.2 or SAS version 9.2 (SAS Institute
Inc, Cary, North Carolina). NONMEM version 7.1
was used for developing the population PK model and
for simulating adult-population PK proﬁles.
The following PK parameters of lurasidone and its
metabolites were estimated using actual elapsed time
from dosing on days 1 and 10 (day 12 in the 160-mg/dDecember 2015cohort): Cmax; Tmax; Cmin at 24 hours postdose on day
10 (day 12 in the 160-mg/d cohort); AUC0–24,
calculated by linear up/log down trapezoidal summa-
tion; AUClast on day 1 only, calculated by linear
up/log down trapezoidal summation; AUC0–1 on
day 1 only, calculated by linear up/log down trape-
zoidal summation and extrapolated to inﬁnity by the
addition of the last quantiﬁable concentration divided
by the terminal elimination rate constant (AUClast þ
Clast/λz); accumulation ratio of Cmax (RCmax), calcu-
lated as (Cmax on day 10)/(Cmax on day 1), when
applicable; accumulation ratio of AUC0–24 (RAUC0–
24), calculated as (AUC0-24 on day 10)/(AUC0-24
on day 1), when applicable; apparent terminal phase
rate constant (λz) on day 1 only, determined by linear
regression of the terminal points of the log-linear
concentration–time curve; t½ on day 1 only, deter-
mined as ln2/λz; apparent oral clearance (CL/F),
calculated for lurasidone only, as dose/AUC0–1 on
day 1 or dose/AUC0–24 on day 10 or 12; apparent
volume of distribution at terminal phase (Vz/F),
calculated for lurasidone only, as dose/(λz  AUC0–1)
on day 1 and dose/(λz  AUC0–24) on day 10 or 12.Tolerability Assessments
Tolerability assessments included the frequency and
intensity (mild, moderate, or severe) of spontaneously
reported adverse events at all study visits. Laboratory
assessments were obtained on days 1 and 10 (day 12 in
the 16 mg/d cohort), and ECG was performed on day 1
(predose and 4 hours postdose) and day 10 (day 12 in
the 16 mg/d cohort). In addition, vital sign measure-
ments (body temperature, supine heart rate, and supine
and standing systolic and diastolic blood pressure) were
obtained in patients in the 20-to 120-mg/d cohorts at
screening; on days –1, 1, 2, 3, 5, 7, 9, 10, and 11; and at
follow-up (on day 18  3). In patients in the 160-mg/d
cohort, vital signs were obtained at screening; on days –
1, 1, 2, 3, 5, 7, 11, 12, and 13; and at follow-up (on day
20  3). A full physical examination was performed at
screening; on day 11 (day 13 in the 160-mg/d cohort);
and at follow-up (on day 18 or 20  3).
Assessment of movement disorders was performed
using the Abnormal Involuntary Movement Scale
(AIMS),12 the Barnes Akathisia Rating Scale (BAS),13
and the Simpson-Angus Rating Scale.14 The Columbia–
Suicide Severity Rating Scale15, used to systematically
assess and track suicidal ideation and behavior, was2791
Clinical Therapeuticsadministered by trained raters on days 1 and 11 (day 13
in the 160-mg/d cohort).
Statistical Analyses
The population for PK analysis consisted of all
patients who received at least 1 dose of study drug and
had at least 1 blood sample obtained for PK analysis.
The sample for safety analyses included all patients
who received at least 1 dose of study drug.
Lurasidone Cmax, AUClast, and AUC0–1 (day 1),
and Cmax and AUC0–24 (day 10 or 12) were the
primary PK parameters; all other parameters were
secondary. PK parameters were summarized by lur-
asidone dose using descriptive statistics. Concentra-
tions below the lower limit of quantitation were
treated as zero for the computation of descriptive
statistics for days 1 and 10/12. The dose proportion-
ality of lurasidone Cmax and AUC0–24 on day 10 (day
12 in the 160-mg/d cohort) was evaluated in all age
groups combined, using a least-squares regression
method. The pediatric data obtained in this study
were compared with the adult-population PK data
derived from a 3-compartment population PK model
from several Phase I to III studies of lurasidone.RESULTS
Patient Characteristics and Disposition
A total of 105 patients were enrolled in the study.
All patients received at least 1 dose of study drug
(safety population), and 102 patients underwent at
least 1 complete PK assessment (PK population). Over-
all, 86% of patients (n ¼ 90) completed all planned
treatment periods. Fourteen subjects discontinued treat-
ment before completing all periods, 9 (8.6%) because
of adverse events. The safety sample overall was 65%
male, with 78% white and 22% black patients and a
mean age, weight, and body mass index of 12.7 years,
51 (18) kg, and 20.6 (4.1) kg/m2, respectively. The
most common diagnosis in the sample was attention
deﬁcit/hyperactivity disorder with aggressive behavior
(78 patients [74%]), followed by bipolar spectrum
disorder (19 [18%]), schizophrenia (5 [5%]), Tour-
ette’s syndrome (2 [2%]), and pervasive developmental
disorders/autistic spectrum disorder (1 [1%]).
Pharmacokinetic Parameters
Mean PK exposure (AUC0–1, AUClast, and Cmax)
on day 1 after single-dose lurasidone administration2792increased with dose from 20 to 80 mg/d (Table I).
Other PK parameters (Tmax, t½, CL/F, and Vz/F) were
not linearly increased across dose groups. Median
Tmax was 2 hours. Mean CL/F and Vz/F values of
lurasidone were similar across all dose groups and
ranged from 317 to 346 L/h and from 6940 to 8700 L,
respectively. Mean t½ on day 1 ranged from 16.2 to
21.3 hours across the 3 dose groups.
On day 10/12, after multiple lurasidone doses, AUC0–
24 and Cmax values were linearly increased across doses
from 20 to 160 mg/d. The slope estimate (95% CI) of
AUC0–24 was 0.90 ng  h/mL (0.74–1.06) and of Cmax
was 0.70 ng/mL (0.52–0.87) across the mean concen-
trations of the doses. The time courses for serum
concentrations over 48 hours on day 1 and over 24
hours on day 10/12 were linearly increased across doses
(Figure 2). However, the linear effect primarily occurred
between the 20-and 80-mg/d doses and appeared attenu-
ated between the 80- and 160-mg/d doses.
The median Tmax value on day 10/12 was inde-
pendent of dose and was 1 to 2 hours across the 5
dose groups. Mean CL/F values of lurasidone on day
10/12 were similar across all dose groups and ranged
from 256 to 323 L/h.
Median Tmax values of the 5 metabolites of lurasi-
done (ID-14283, ID-14326, ID-11614, ID-20219, and
ID-20220) were generally similar to the lurasidone Tmax,
indicating rapid metabolism. Minimal accumulations of
ID-14283 and ID-14326 were observed after 10 days of
lurasidone dosing over the dose range of 20 to 80 mg/d,
and no obvious accumulations of ID-11614, ID-20219,
or ID-20220 was observed, likely due to the relatively
short t½ values of these metabolites. Mean PK exposure
(AUC0–24, AUClast, and Cmax) of the 3 active metabolites
of lurasidone (ID-14283, ID-14326, and ID-11614)
were generally linearly increased across doses on days
1 and 10/12. Mean serum concentrations of metabolites
ID-14283, ID-14326, ID-11614, and ID-20220 were
generally lower than lurasidone concentrations on days
1 and 10/12, whereas mean serum ID-20219 concen-
trations were similar to lurasidone concentrations (data
not shown).
The AUC0–24,ss (Figure 3) and Cmax (data not
shown) values across the dose range studied (20–160
mg/d) were generally similar to values at steady state
observed in the adult-population PK model; however,
younger children (aged r9 years) appeared to have
had slightly higher mean exposures, although this was
not formally evaluated.Volume 37 Number 12
Table 1. Pharmacokinetic parameters for lurasidone on day 1 (single dose) and days 10 or 12 (multiple
dose), mean (SD).
Lurasidone Dose
20 mg 40 mg 80 mg 120 mg 160 mg
Parameter n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Day 1
Cmax, ng/mL 16 24.4 (14.1) 24 38.4 (22.4) 55 68.2 (37.5) – – – –
AUC0-1, ng  h/mL 16 84 (48) 19 153 (70) 50 328 (163) – – – –
AUC0-last, ng  h/mL 16 78 (45) 24 140 (65) 54 300 (140) – – – –
CL/F, L/h 16 346 (245) 19 317 (144) 50 324 (240) – – – –
tmax, h 16 2.0 (0.9) 24 1.8 (0.8) 55 2.2 (1.0) – – – –
t ½, h 16 16.2 (4.7) 20 21.3 (7.3) 50 16.8 (5.4) – – – –
Vz/F, L 16 6940 (3030) 19 8700 (3500) 50 7640 (5390) – – – –
Day 10 or 12
Cmax, ng/mL 16 30.0 (18.0) 21 36.2 (17.5) 17 80.0 (59.6) 16 94.2 (46.6) 13 99.7 (44.3)
AUC0-24, ng  h/mL 16 115 (72) 21 154 (67) 17 387 (194) 16 494 (271) 13 590 (227)
CL/F, L/h 16 256 (172) 21 323 (173) 17 262 (144) 16 315 (182) 13 313 (126)
tmax, h 16 2.3 (1.3) 21 1.6 (0.9) 17 2.2 (1.6) 16 2.3 (1.1) 13 2.3 (1.0)
RAUC0-24 16 1.66 (0.58) 20 1.30 (0.28) 15 1.37 (0.35) – ND – ND
RCmax 16 1.40 (0.79) 20 1.16 (0.55) 15 1.17 (0.63) – ND – ND
R.L. Findling et al.Tolerability
The most common adverse events across dose
cohorts were somnolence (42%), sedation (18%),
nausea (17%), and vomiting (15%) (Table II). Most
(70%) adverse events were mild or moderate in
intensity. The percentages of patients reporting
severe adverse events were 0%, 4.0%, 15.8%,
4.0%, and 0% for the 20-, 40-, 80-, 120-, and 160-
mg/d doses, respectively. All of the patients in the 120-
mg/d dose cohort aged 6 to 9 years experienced
moderate or severe vomiting and sedation or
somnolence; therefore, after study team review,
treatment in the 6- to 9-year-old patient group was
not escalated to the 160-mg/d dose.
Adverse events leading to study discontinuation
were vomiting (2 patients with the 40-mg/d dose;
1 with 80 mg/d), somnolence (1 with 40 mg/d; 1 with
80 mg/d), akathisia (1 with 80 mg/d), Parkinsonism
(1 with 80 mg/d), blurred vision (1 with 80 mg/d),
and dystonia (1 with 120 mg/d).
Two serious adverse events were reported. One
patient (a 10-year-old boy) experienced Parkinsonism
on day 6 of treatment with lurasidone 80 mg/d and
was discontinued on day 6; the event resolvedDecember 2015spontaneously. The second subject (a 13-year-old girl)
experienced dystonia 4 days after the initiation of
treatment with lurasidone 80 mg/d. The investigator
assessed the event of dystonia as moderate in intensity,
intermittent, and related to the study drug. At the
family’s request, the patient was admitted to the
hospital. On day 5, the patient was admitted to
the clinical site to complete the study, and she
remained an inpatient in the clinical site. While at
the clinical site, the patient received a planned 120-mg/d
dose of lurasidone on day 6. Study medication was
discontinued on day 7 by the investigator. The subject
received benztropine from days 5 through 8 for the
treatment of dystonia, which resolved on day 8. No
deaths during the study were reported.
A low frequency of movement disorder was
reported (akathisia, 2%; Parkinsonism, 1%). At all
doses and ages combined, the mean (SD) changes from
baseline to day 10/12 were 0 (0.3) on the BAS and 0.1
(0.44) on the Simpson-Angus Rating Scale. On the
AIMS scores for severity, incapacitation, and patient
awareness of abnormal movements, the mean (SD)
changes from baseline to day 10/12 were 0 (0.11),
0 (0.0), and 0 (0.11), respectively.2793
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Figure 2. Mean serum lurasidone concentration–time profile on treatment day 1 (A) and day 10 or 12 (B) on
a semilogarithmic scale.
Clinical TherapeuticsNo clinically signiﬁcant changes in laboratory test
measurements, vital sign measurements, or ECG ﬁnd-
ings were reported. No clinically signiﬁcant changes in
weight were observed. No suicidal ideation or behav-
ior was reported by any patient during the study.DISCUSSION
Relatively few studies have reported on the PK proﬁle
of atypical antipsychotic agents in children and
adolescents.16–18 The present study is the ﬁrst to
examine the PK proﬁle of lurasidone in child and
adolescent patients. The results suggest that lurasi-
done exposure, after the administration of single and
multiple doses of 20 to 160 mg/d in patients aged 6 to
17 years, was generally similar to that observed in
adults, although slightly higher exposure levels were
observed in the 6–9-year cohort at some doses (eg,2794120 mg). A linear dose effect on drug exposure was
evident with lurasidone 20 to 80 mg/d on day 1
(AUC0–1, AUClast, and Cmax), and also at steady state
with lurasidone 20 to 160 mg/d on day 10/12 (AUC0–24
and Cmax). Similar linear effects of dose on exposure to
all 3 active metabolites of lurasidone were also generally
seen after the administration of single and multiple doses.
The adverse event proﬁle of lurasidone was qual-
itatively similar to that reported in adult patients;
however, there was a higher frequency of somnolence
in the current pediatric sample (42%; combined doses)
compared with the rate reported in adults in short-
term trials in schizophrenia (11%; pooled data, N =
1004).19 Higher rates of somnolence in children (vs
adults) treated with atypical antipsychotic agents have
previously been reported.20 There were few adverse
events related to movement disorders, a ﬁnding
consistent with those from the BAS, Simpson-AngusVolume 37 Number 12
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Figure 3. Lurasidone exposure (AUC0–24,ss) in pediatric patients compared with adult patients, after multiple-
dose administration of lurasidone 20 to 160 mg/d. The open circles represent the observed
AUC0-24,ss by age group in the present study in children. The boxplot represents the simulated
distribution of AUC0-24,ss values from 5000 patients using an adult population PK model.
Demographic covariate vectors were sampled from the empirical distribution of the observed PK
dataset in adults.
R.L. Findling et al.Rating Scale, and AIMS assessments. Adverse events
were more frequent at the higher doses (120 and 160
mg/d), particularly in younger patients. In addition,
discontinuations due to adverse events appeared to
have been dose related; 75% of patients who discon-
tinued treatment received lurasidone doses of Z80
mg/d. Thus, the PK and tolerability results from this
study suggest that the dose range of 20 to 80 mg/d
provides adequate serum concentrations, but with
improved tolerability compared with higher doses.
These PK ﬁndings from a child and adolescent
population suggest that the therapeutic dose range
for lurasidone may be similar in this population
compared to adults, although, doses ≥120 mg/d were
less tolerated in the younger population. Based onDecember 2015these study results, the dose range of 20 to 80 mg/d
has been studied in efﬁcacy trials with lurasidone in
child and adolescent populations.
Some limitations of the study design may limit the
interpretation of the data. In particular, although
sample sizes were sufﬁcient for pharmacokinetic anal-
yses, they were too small to allow for reliable
conclusions about the tolerability of various doses of
lurasidone in speciﬁc age groups. The diagnoses of the
current patient population (74% with attention deﬁ-
cit/hyperactivity disorder with aggressive behavior)
limit the generalizability of these results to other
disorders. Finally, the study did not assess the effect
of hepatic or renal impairment on lurasidone exposure
in this child and adolescent population.2795
Table II. Treatment-emergent adverse events by dose cohort (number, %).
Parameter
Dose
All Dose Cohorts
(N ¼ 105)
20 mg
(n ¼ 20)
40 mg
(n ¼ 25)
80 mg
(n ¼ 19)
120 mg
(n ¼ 25)
160 mg
(n ¼ 16)
Any TEAE 4 (20) 17 (68) 17 (90) 24 (96) 16 (100) 78 (74)
TEAE
Nausea 1 (5) 3 (12) 6 (32) 2 (8) 6 (38) 18 (17)
Dizziness 1 (5) 2 (8) 0 1 (4) 0 4 (4)
Upper abdominal pain 1 (5) 0 1 (5) 4 (16) 0 6 (6)
Somnolence 0 11 (44) 7 (37) 16 (64) 10 (63) 44 (42)
Sedation 0 3 (12) 5 (26) 7 (28) 4 (25) 19 (18)
Vomiting 0 4 (16) 4 (21) 5 (20) 3 (19) 16 (15)
Dyskinesia 0 1 (4) 3 (16) 1 (4) 0 5 (5)
Insomnia 0 0 3 (16) 0 1 (6) 4 (4)
Anxiety 0 0 1 (5) 1 (4) 4 (25) 6 (6)
Dystonia 0 0 0 4 (16) 2 (13) 6 (6)
Diarrhea 0 0 0 3 (12) 0 3 (3)
Dry mouth 0 0 0 3 (12) 0 3 (3)
Vision blurred 0 0 0 2 (8) 1 (6) 3 (3)
TEAE ¼ treatment-emergent adverse event.
Clinical TherapeuticsCONCLUSIONS
In the present single and multiple ascending-dose
study, the ﬁrst to examine the PK proﬁle of lurasidone
in a pediatric population, lurasidone and its 3 active
metabolites exhibited dose-proportional exposure lev-
els that were generally similar to what has been
observed in adults. The adverse events proﬁle was
qualitatively similar to results reported in prior studies
in adults. The results from this study suggest that
lurasidone doses of o120 mg/d were better tolerated
than were higher doses, especially in younger children.
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